Lafutidine

Lafutidine

300px
Systematic (IUPAC) name
2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
Identifiers
CAS Number	118288-08-7 Y
ATC code	A02BA08 (WHO)
PubChem	CID: 5282136
ChemSpider	4445337 N
UNII	49S4O7ADLC Y
KEGG	D01131 Y
Chemical data
Formula	C22H29N3O4S
Molecular mass	431.54 g/mol
SMILES C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)C[S+](CC3=CC=CO3)[O-]
InChI InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- N Key:KMZQAVXSMUKBPD-DJWKRKHSSA-N N
NY (what is this?)  (verify)

Lafutidine (INN) is a second generation histamine H₂ receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use

Lafutidine is used to treat gastric ulcers, duodenal ulcers, stomach ulcers as well as wounds in the lining of the stomach associated with acute gastritis and acute exacerbation of chronic gastritis.

Adverse effects

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea, vomiting and dizziness.

Mechanism of action

Like other H₂ receptor antagonists it prevents the secretion of gastric acid. It also activates calcitonin gene-related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of Helicobacter pylori to gastric cells.

Trade names

It is marketed in Japan as Stogar by UCB and in India as Lafaxid by Zuventus Healthcare.